Click here to download a PDF of the paper.

Research team led by Dr. Emanuel Petricoin publishes new methodology for analyzing reverse phase arrays.

Researchers are using infrared detection technology from LI-COR Biosciences to improve results of reverse phase arrays used to analyze drug targets and pathway networks in clinical studies. A paper published by Dr. Emanuel Petricoin in a recent issue of CLINICAL PROTEOMICS JOURNAL compares the use of colormetric versus infrared detection for reverse-phase protein microarrays.

Petricoin’s team reports that infrared technology brings significant advantages to reverse phase array analysis. The paper states that the assay has sensitivity equivalent tyramide signal amplification with the added feature of two channels or colors, effectively doubling the number of endpoints that can be analyzed with a fixed number of arrays. The researchers note that most clinical samples are limiting, while the number of potential signaling endpoints is quite large. Therefore any ability to multiplex the process can have substantial practical impact on sample utilization.